Title of article
Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified
Author/Authors
Green، نويسنده , , H. and Stهl، نويسنده , , O. and Bachmeier، نويسنده , , K. and Bنcklund، نويسنده , , L.M. and Carlsson، نويسنده , , L. and Hansen، نويسنده , , J. and Lagerlund، نويسنده , , M. and Norberg، نويسنده , , B. and Franzén، نويسنده , , إ. and إleskog، نويسنده , , A. and Malmstrِm، نويسنده , , A.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2011
Pages
9
From page
145
To page
153
Abstract
We investigated the efficacy and safety of single-agent pegylated liposomal doxorubicin (PLD) as first-line treatment for elderly women with advanced breast cancer and evaluated predictive markers for response and toxicity.
-five women ⩾65 years received 40 mg/m2 PLD every 28 days. Time to treatment failure (TTF), response rate, time to progression (TTP) and overall survival (OS) was calculated. The ABCB1 single nucleotide polymorphisms (SNP), tumor MRN complex, and TOPOIIα were analyzed. A mean of 7.4 cycles PLD were administered and TTF was 5.5 months and OS 20.6 months.
SNPs were found to correlate to both efficacy and toxicity, while tumor expression of the MRN complex and TOPOIIα correlated to TTP.
a safe and effective treatment for elderly breast cancer patients. Also potential predictive markers were identified.
Keywords
Anthracycline , Topoisomerase II? , Elderly , MRN complex , genotype , metastatic breast cancer
Journal title
Cancer Letters
Serial Year
2011
Journal title
Cancer Letters
Record number
1820722
Link To Document